ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients,... ...http://feeds.reuters.com/~r/reuters/INhealth/~3/4fypFjvU8kU/novartis-gains-u-s-approval-for-delayed-ms-drug-idINKBN1FX0LY
Sandoz will lead commercialisation in North America and the European Union, while Biocon will lead commercialisation in the rest of the world. ...http://www.moneycontrol.com/news/buzzing-stocks/biocon-gains-4global-partnershipsandoz-for-biosimilarsimmunology-oncology_10377481.html
These biosimilars are in early stages of development. As the cost incurred during the early stages are not significant we don’t expect our Ramp;D... ...http://www.moneycontrol.com/news/business/biocon-ceo-arun-chandavarkar-says-sandoz-tie-up-to-help-them-target-multi-billion-dollar-biosimilar-opportunity_10379021.html
Posted by Equitymaster Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.31% while the Hang... ...http://www.equitymaster.com/tm/tm.asp?date=1/19/2018&title=Indian-Share-Markets-Open-Flat-Yes-Bank-Top-Gainer
Indian biotechnology major Biocon on Thursday said it would develop, make and market new drugs in immunology and oncology for patients worldwide in... ...http://www.prokerala.com/news/articles/a803598.html
Novartis was created in 1996 through...